Evidence map›Paper›PMID 42483195›Full record

ArticleFrontiers in immunology2026

Efferocytosis-associated Mrc1

Wenxuan Xiang, Xiaohong Song, Xiangyu Xian, Hao Zhou, Bingli Xu, Lei Zhou, Dan Yang, Yuehong Zheng

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenxuan Xiang *Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiaohong Song *Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiangyu XianDepartment of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hao ZhouDepartment of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Bingli XuDepartment of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Lei ZhouDepartment of Vascular Surgery, The Seventh People's Hospital of Chongqing, Chongqing, China.
Dan YangDepartment of Computational Biology and Bioinformatics, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuehong ZhengDepartment of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Abdominal aortic aneurysm (AAA) is a progressive vascular disease characterized by chronic inflammation, extracellular matrix degradation, and aortic wall remodeling, yet effective pharmacological therapies remain lacking and how macrophage state heterogeneity contributes to disease progression and defective inflammation resolution remains incompletely understood. Methods: We combined single-cell RNA sequencing of elastase-induced murine AAA with pathway, cell-cell communication, trajectory, and regulon analyses, and validated key findings Results: Single-cell transcriptomic analysis identified four macrophage subsets in AAA, comprising Thbs1 Conclusions: AAA is characterized by an imbalance between inflammatory and efferocytosis-associated macrophage states. ERK-associated dysfunction of Mrc1

Indexed as

Aortic Aneurysm, AbdominalIntercellular Signaling Peptides and ProteinsMacrophagesMAP Kinase Signaling SystemAnimalsc-Mer Tyrosine KinaseDisease Models, AnimalDisease ProgressionEfferocytosisGrowth Arrest-Specific Protein 6MaleMiceMice, Inbred C57BLc-Mer Tyrosine KinaseGrowth Arrest-Specific Protein 6Intercellular Signaling Peptides and ProteinsMertk protein, mouseabdominal aortic aneurysmefferocytosisERK signalingmacrophage heterogeneitymafMERTK

Identifiers

PMID42483195
PMCPMC13384856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.